Suppr超能文献

5-羟色胺1样受体激动剂可增强清醒状态。

5-HT1-like receptor agonists enhance wakefulness.

作者信息

Dzoljic M R, Ukponmwan O E, Saxena P R

机构信息

Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, The Netherlands.

出版信息

Neuropharmacology. 1992 Jul;31(7):623-33. doi: 10.1016/0028-3908(92)90140-k.

Abstract

The effects of four 5-HT1-like receptor agonists (8-OH-DPAT, RU 24969, BEA 1654 and 5-carboxamidotryptamine) and some putative 5-HT1-like receptor antagonists on vigilance were examined in an attempt to clarify the role of 5-HT1-like receptors in the sleep-waking pattern of rats. Both 8-OH-DPAT (0.5-2.0 mg/kg, s.c.) and RU 24969 (0.5-2.0 mg/kg, s.c.) increased wakefulness and the latencies of slow wave and rapid eye movement (REM) sleep. The slow wave and REM sleep were correspondingly decreased or completely abolished. The two other 5-HT1-like receptor agonists had either a slight (BEA 1654, 1.0-5.0 mg/kg, s.c.) or no (5-carboxamidotryptamine, 0.5-2.0 mg/kg, s.c.) effect on sleep pattern. The arousal effect of 8-OH-DPAT was further potentiated in rats pretreated with reserpine (2.5 mg/kg, i.p.; 18 hr before 8-OH-DPAT). The non-selective 5-HT1-like and 5-HT2 receptor antagonist, methiothepin (2.0 mg/kg, i.p.) and the beta-adrenoceptor antagonist propranolol (16.0 mg/kg, s.c.), which is a putative antagonist at 5-HT1A and 5-HT1B receptor subtypes, significantly potentiated the arousal effect of RU 24969. The putative 5-HT1A and 5-HT1B receptor antagonist, cyanopinolol (4.0 mg/kg, s.c.), mixed 5-HT1A receptor agonist/antagonist MDL 72832 (1.0 mg/kg, s.c.) and the alpha 1-adrenoceptor antagonist prazosin (2.0 mg/kg) did not affect the vigilance, altered by RU 24969. These results suggest that the arousal effect of 5-HT1-like receptor agonists is probably not mediated by any of the subtypes of 5-HT1-like receptors or by an activation of a noradrenergic system.

摘要

研究了四种5-HT1样受体激动剂(8-羟基二丙胺基四氢萘、RU 24969、BEA 1654和5-羧酰胺色胺)以及一些假定的5-HT1样受体拮抗剂对警觉性的影响,以阐明5-HT1样受体在大鼠睡眠-觉醒模式中的作用。8-羟基二丙胺基四氢萘(0.5-2.0毫克/千克,皮下注射)和RU 24969(0.5-2.0毫克/千克,皮下注射)均增加了觉醒以及慢波睡眠和快速眼动(REM)睡眠的潜伏期。慢波睡眠和REM睡眠相应减少或完全消失。另外两种5-HT1样受体激动剂对睡眠模式要么有轻微影响(BEA 1654,1.0-5.0毫克/千克,皮下注射),要么没有影响(5-羧酰胺色胺,0.5-2.0毫克/千克,皮下注射)。在用利血平(2.5毫克/千克,腹腔注射;在注射8-羟基二丙胺基四氢萘前18小时)预处理的大鼠中,8-羟基二丙胺基四氢萘的唤醒作用进一步增强。非选择性5-HT1样和5-HT2受体拮抗剂甲硫哒嗪(2.0毫克/千克,腹腔注射)以及β-肾上腺素能受体拮抗剂普萘洛尔(16.0毫克/千克,皮下注射,它被认为是5-HT1A和5-HT1B受体亚型的拮抗剂)显著增强了RU 24969的唤醒作用。假定的5-HT1A和5-HT1B受体拮抗剂氰氧洛尔(4.0毫克/千克,皮下注射)、5-HT1A受体激动剂/拮抗剂混合剂MDL 72832(1.0毫克/千克,皮下注射)以及α1-肾上腺素能受体拮抗剂哌唑嗪(2.0毫克/千克)均未影响由RU 24969改变的警觉性。这些结果表明,5-HT1样受体激动剂的唤醒作用可能不是由5-HT1样受体的任何亚型介导的,也不是由去甲肾上腺素能系统的激活介导的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验